Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-10-02-2004, Volume 28, Issue 10

Big Pharma is ramping up capital spending in parenteral manufacturing at the same time that contract manufacturers are completing their own major investment programs.

Related Content:

Drug DeliveryBio/Pharma BusinessOutsourcingManufacturingOutsourcing OutlookDevelopmentParenteralsDosage FormsManufacturing, Parenterals and InjectablesManufacturing, Drug ProductsPharmaceutical Technology-10-02-2004
Abzena Expands Microbiology Laboratory Space
BIO 2024: CDMOs Focus on Complex Technical Challenges to Boost Startup Biotechs
Novartis and Monte Rosa Therapeutics Form $2.1 Billion Global License Agreement for MGD-based Therapeutics